





# Barcelona Medical Destination: High value, high complexity

#### **Patrick Torrent**

Executive director
Barcelona Medical Destination - Catalan Tourist Board























#### Barcelona, the capital


Cosmopolitan, modern and Mediterranean character

Welcoming & compact
Well connected















## A healthy city with the best medical facilities









#### **Barcelona Medical Destination**

#### An excellent choice for advanced medical care

A program run by the Catalan Tourist Board and Barcelona Tourist Board, in partnership with the Barcelona Medical Centre and Barcelona International Hospitals associations, which bring together the leading medical centres in Catalonia and, particularly, in Barcelona

















#### Why Catalonia?

- The **health sector** is the 4th largest sector in employment, with over 230.000 dedicated professionals.
- The EU recognizes that Catalonia has a mature healthcare system in organization, innovation, research and efficiency.

 The average life expectancy is 80 years for men and 86 years for women

 Spain holds the 7th position in the overall health system performance rating of WHO (Tandon et alter, 2000)







### Why Catalonia?

- Barcelona is a city with one the highest health levels in Europe.
- It has the best medical teams and professionals for patient service.
- They are equipped with the most advanced technology and equipment for patient care.
- Barcelona meets the most attractive medical package in Europe.
- Its hospitals cover all specialties in the field of medicine.







#### **Leading specialties and procedures**



Aesthetic & reconstructive surgery



Cardiovascular medicine



Complex pediatrics (0-18)



Dermatology



Digestive surgery & metabolic diseases



Gynecology



Neurorehabilitation



**Neuroscience** 



Obstetrics & Fetal Medicine



Oncology & hematology & radiotherapy



Ophthalmology



Otolaryngology



Reproductive Medicine



Transplants



Traumatology & orthopedics



Urology & nephrology






























































High risk, high complex

Complex procedures

Minimally Invasive Surgeries

Well-being

**Prevention** 







High risk, high complex

**Complex procedures** 

Minimally Invasive Surgeries


Well-being

**Prevention** 















High risk, high complex

Complex procedures

Minimally Invasive Surgeries

Well-being

IVF
Cosmetic-reconstructive
surgery

Prevention







High risk, high complex

Complex procedures

Minimally Invasive Surgeries

Well-being

**Prevention** 







#### Strength of the medical offer of Barcelona

High critical mass of Knowledge







#### **Barcelona Medical Destination: a long history**



Josep Trueta, MD
(1897-1977)
General Surgeon
The Trueta Method for
treatment of open
fractures



Ignasi Barraquer, MD
(1887-1965)
Ophthalmologist
The Barraquer Method for cataract surgery
(phacoeresis)







#### Physicians: Knowledge and expertise



Valentí Fuster

MD, PhD

Director,
Institute of
Cardiology

Mount Sinai Hospital
(New York)



Joan Massagué
PhD
Director,
Sloan-Kettering
Cancer Research
Institute
(New York)



José Baselga
PhD
Director,
Sloan-Kettering
Cancer Center
(New York)



Pedro Alonso
PhD
Director,
Director of
WHO's Global
Malaria
Programme







#### Physicians: Knowledge and expertise



Jaume Mora, MD, PhD (Pediatrical Oncologist)



Josep Tabernero, MD, PhD, MsC (Oncologist)



Armando Lopez Guillermo, MD, PhD (Hematology)



Antonio Lacy MD, PhD General Surgery



Antonio Alcaraz MD, PhD Uroglogy



Benjamin Guix MD, PhD Radiooncology







#### Physicians: Knowledge and expertise



MD, PhD
Cardiology



Rafael Barraquer, MD, PhD (Ophthalmologist)



Eduard Gratacós, MD, PhD Fetal Medicine



Humberto
Villavicencio
MD, PhD (Urologist)



Ramon Cugat, MD PhD (Traumatologist)



Francesc Palau, MD, PhD (Medical Geneticist)







#### Strength of the medical offer of Barcelona

Health Care Teamwork







#### To achieve good results: organization & team work









#### Strength of the medical offer of Barcelona

Postgraduate education & training







## **Post-graduate training**









## **Staff continuous training**









#### Strength of the medical offer of Barcelona

**Patient** experience programs







## A comprehensive approach to patients










## A comprehensive approach to patients









#### Strength of the medical offer of Barcelona

Research & Innovation







#### **Translational Research and Clinical Trials**



Home > Current News > Blog > Catalonia, among the top 10 in Europe in clinical trials

#### Catalonia, among the top 10 in Europe in clinical trials

Catalonia is among the top 10 countries in Europe in terms of participation in clinical trials and among the top 20 in the world; looking at oncology alone, it is in the European Top 5 and the global Top 10. This November, Barcelona hosted the international Clinical Trials Europe event: a great time to look back over the factors that have made the BioRegion a benchmark in attracting trials from all the major pharmaceutical companies in the world, and also at the future challenges this sector is facing.

27.11.2019













Remote working in the BioRegion: a new reality that is here to stay? 27.01.2021

Recent entries

the Catalan biomedical

ecosystem 23.02.2021

"Many more role models are

needed." Women's presence in

NÚRIA PELÁEZ 🛅



#### **Related Contents**

Five researchers from the BioRegion receive ERC Proof of







## The UB is once more the leading institution in Spain with most researchers among the highly-cited worldwide



Researchers linked to the UB appearing in the Clarivate Analytics 2021 list.

#### 16/11/2021

#### Recerca

The University of Barcelona appears one more year as the leading university in Spain with the most researchers among the most influential worldwide and it is the second most influential research centre in Spain, following CSIC (Spanish National Research Council). The ranking, published by Clarivate Analytics, identifies the experts who lead the projects with the highest international scientific impact in various areas of study.








#### Pioneer research in oncology



#### SHARE

RESEARCH ARTICLE | CANCER







Guillem Pascual-Pasto<sup>1,2</sup>, Miriam Bazan-Peregrino<sup>3</sup>, Nagore G. Olaciregui<sup>1,2</sup>, Camilo A. Restrepo-Perdomo<sup>4</sup>, Ana Mato-Berciano<sup>3</sup>, Daniela Ottaviani<sup>5,6</sup>, Klaus Weber<sup>7</sup>, Genoveva Correa<sup>1,2</sup>, Sonia Paco<sup>1,2</sup>, Monica Vila-Ubach<sup>1,2</sup>, Maria Cuadrado-Vilanova<sup>1,2</sup>, Helena Castillo-Ecija<sup>1,2</sup>, Gaia Botteri<sup>1,2</sup>, Laura Garcia-Gerique<sup>1,2</sup>, Helena Moreno-Gilabert<sup>1,2</sup>, Marta Gimenez-Aleiandre<sup>3</sup>, Patricia Alonso-Lopez<sup>3</sup>, Marti Farrera-Sal<sup>3</sup>, Silvia Torres-Manion<sup>8</sup>, Dolores Ramos-Lozano<sup>8</sup>, Rafael Moreno<sup>8</sup>, Isabelle Aerts<sup>5,6</sup>, François Doz<sup>5,9</sup>, Nathalie Cassoux<sup>5,9,10</sup>, Elodie Chapeaublanc<sup>5,6</sup>, Montserrat Torrebadell<sup>1,2</sup>, Monica Roldan<sup>1,4</sup>, Andrés König<sup>11</sup>, Mariona Suñol<sup>4</sup>, Joana Claverol<sup>1,12</sup>, Cinzia Lavarino<sup>1,2</sup>, Torres Carmen de<sup>1,2,\*</sup>, Ligia Fu<sup>13</sup>, François Radvanyi<sup>5,6</sup> Francis L. Munier<sup>14</sup>, Jaume Catalá-Mora<sup>15</sup>, Jaume Mora<sup>1,2</sup>, Ramón Alemany<sup>8</sup>, Manel Cascalló<sup>3</sup>, Guillermo L. Chantada<sup>1,2,16,17</sup> and Angel M. Carcaboso 1,2,†

<sup>1</sup>Institut de Recerca Sant Joan de Deu, Barcelona 08950, Spain.

<sup>2</sup>Pediatric Hematology and Oncology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

<sup>3</sup>VCN Biosciences, Sant Cugat del Valles, Barcelona 08174, Spain.

<sup>4</sup>Pathology, Hospital Sant Joan de Deu, Barcelona 08950, Spain

5Institut Curie, CNRS, UMR144, SIREDO Oncology Center, 75248 Paris, France.

<sup>6</sup>Institut Curie, PSL Research University, 75248 Paris, France.

<sup>7</sup>AnaPath GmbH, Oberbuchsiten 4625, Switzerland.

<sup>®</sup>Translational Research Laboratory, IDIBELL-Institut Catala d'Oncologia, 08908, L'Hospitalet de Llobregat, Barcelona, Spain,

9Paris Descartes University, 75006 Paris, France.

10Institut Curie, Ophthalmic Oncology, 75248 Paris, France.

11 Vivotecnia Research S.L., Tres Cantos, Madrid 28760, Spain.

12 Clinical Trials Unit, Hospital Sant Joan de Deu Barcelona 08950, Spain

<sup>13</sup>Pediatric Hematology-Oncology, Hospital Escuela Universitario, Tegucigalpa, Honduras.

14Hôpital Ophtalmique Jules-Gonin, Lausanne 133, Switzerland.

15Ophthalmology, Hospital Sant Joan de Deu, Barcelona 08950, Spain.

<sup>16</sup>Hospital de Pediatria JP Garrahan, Buenos Aires 1245, Argentina

17CONICET, Buenos Aires 1245, Argentina.

4<sup>†</sup>Corresponding author. Email: amontero@fsjd.org

√\* Deceased.

- Hide authors and affiliations

Science **Translational** Medicine Vol 11, Issue 476 23 January 2019 Table of Contents ARTICLE TOOLS Email Download Powerpoint Print Save to my folders C Request Permissions ♠ Alerts Citation tools → Share **APPLY** NOW.

**Publication** in Science 2019: Oncolytic virus to attack selectively a tumor in children

Science Translational Medicine, 23, Ian 2019







# CAR-T ARI-0001 (in-house developed) Patients with acute lymphoblastic leukaemia >25 years










# Start-up: Nanofiber membranes to apply chemotherapy locally













INSTITUTIONAL

September 18 2020

# Spin-off Reveal Genomics born to develop innovative diagnostic tests in oncology


Reveal Genomics' first goal will be to develop diagnostic tools based on complex genomic data for patients with advanced breast cancer.

















### Strength of the medical offer of Barcelona


Upfront technology







### **Barcelona Super-Computing Center**

















# **Integrated surgical theaters**









## **Vectra 360º - Skin malignance diseases**









### Strength of the medical offer of Barcelona

Quality & Safety
Programs







### **Quality & patient safety: culture and practice**

Evolució dels indicadors analitzats. Hospitals SISCAT, 2016-2018

Efectivitat	2016	2017	2018
Mortalitat a 30 dies per malalties seleccionades (%)*	12,1	12,0	13,4
Mortalitat hospitalària (a l'alta) per malalties seleccionades (%)*	8,1	8,0	8,
Mortalitat a 30 dies per IAMEST (%)*	8,8	8,7	8,8
Mortalitat hospitalària (a l'alta) per IAMEST (%)*	6,9	6,6	6,0
Mortalitat a 30 dies per IAMEST (sense trasllats) (%)*	9,4	9,2	9,
Mortalitat hospitalària (a l'alta) per IAMEST (sense trasllats) (%)*	7,2	7,2	7,
Mortalitat a 30 dies per insuficiència cardíaca congestiva (%)*	13,6	13,5	15,
Mortalitat hospitalària (a l'alta) per insuficiència cardíaca congestiva (%)*	8,6	8,3	8,9
Mortalitat a 30 dies per ictus (%)*	18,2	18,0	19,
Mortalitat hospitalària (a l'alta) per ictus (%)*	13,2	13,3	13,
Mortalitat a 30 dies per fractura de coll de fèmur (%)*	7,6	7,3	9,0
Mortalitat hospitalària (a l'alta) per fractura de coll de fèmur (%)*	4,6	4,5	4,
Reingressos a 30 dies per causes seleccionades (%)	9,8	9,8	
Reingressos a 30 dies per complicacions de la diabetis (%)	4,6	4,6	
Reingressos a 30 dies per malaltia pulmonar obstructiva (%)	16,3	16,0	
Reingressos a 30 dies per insuficiència cardíaca congestiva (%)	14,3	14,2	
Mortalitat a 3 mesos en trombòlisi intraven. aillada per ictus isquèmic	19,4	14,0	11,0
Superv a 3 mesos amb recuperació completa en trombòlisi intraven aillada per ictus isquèmic	37,0	34,2	33,
Donants cadàver vàlids (%)	66,7	68,4	58,
Negatives familiars (%)	14,9	13,7	19,0
Índex d'organs trasplantats per donant vàlid	2,4	2,6	2,
Donants vàlids de mort en asistòlia (%)	33,3	35,1	36,
Donació de viu en el trasplantament renal (%)	19,5	17,1	16,0
Casos incidents en diàlisi amb diàlisi peritoneal (%)	16,3	-	14,
Casos incidents en diàlisi amb hemodiàlisi i amb un FAVI com a primer accés vascular (%)	44,6	-	40,
Casos en tractament substitutiu renal amb un tractament renal funcionant (%)	55,3	-	57,

<sup>\*</sup> En el 2018 s'han produït dos grans canvis en el CMBD-HA; per una banda el model emprat en la comunicació de les dades, i per l'altra el catàleg de classificació de maialties i procediments. Totes aquestes modificacions fan que sigui dificil interpretar els possibles canvis de tendência que es poden observar en els indicadors. Per aquest motiu es prega la màxima cautela a l'hora de comparar i valorar els resultats provisionais d'aquest any 2018 amb els d'any anteriors.

Seguretat	2016	2017	2018
Bacterièmia de catèter venós global (per 1.000 dies d'estada)*	0,18	0,17	0,20
Bacterièmia de catèter venós central (per 1.000 dies d'estada)*	0,11	0,09	0,09
Bacterièmia de catèter venós central associada a la nutrició parenteral (per 1.000 dies NP)*	1,88	1,88	1,74
Infecció de localització quirúrgica d'O/E en la cirurgia electiva de colon (%)*	6,1	4,7	5,0
Taxa de profilaxis adequada de cirurgia colon (%)*	81,0	79,0	85,1
Infecció de localització quirúrgica d'O/E en la cirurgia electiva de recte (%)*	7,7	8,0	9,4
Taxa de profilaxis adequada de cirurgia recte (%)*	76,0	80,8	85,1
Infecció de localització quirúrgica d'O/E en la cirurgia protètica de genoll (%)*	1,32	-	1,23
Infecció de localització quirúrgica d'òrgan-espai en la cirurgia protètica de maluc*	-	-	1,38
Taxa de caigudes en pacients hospitalitzats (per 1.000 hospitalitzacions)	-	-	1,79
Percentatge d'embolisme pulmomar (%)	0,14	0,15	-
Mortalitat en GRD de baixa mortalitat (%)	0,07	0,06	-
Mortalitat en pacients que han desenvolupat complicacions (%)	29,0	34,0	-
Úlceres per pressió (%)	0,72	0,75	-

<sup>\*</sup> Les dades totals de Catalunya corresponen a tots els hospitals públics i privats que notifiquen al VINCat

#### Regional and hospital level:

- Effectivity
- Safety
- Satisfaction
- Adecuay of care







### Strength of the medical offer of Barcelona

Highly effective health care system









**How Spain Became the World Leader in Organ Donations** 







### Strength of the medical offer of Barcelona

**Biomedical Industry** 









High critical mass of Knowledge

Health Care Teamwork Postgraduate education & training

Patient experience programs

Research & Innovation

Upfront technology

Quality & Safety Programs

Highly effective health care system

Biomedical Industry









# World's first full robotic transvaginal kidney transplant (2015)









# A child with an aggressive brain tumor is successfully treated with an adult lung cancer medication









# Among the best Children's Hospitals in the world for Neuroblastoma



15 SEPTEMBER 2021

Published in: CLINICAL PRACTICE, MAIN, RESEARCH



An oncological patient in a waiting room of the Sant Joan de Déu Hospital Barcelona







### Milestone



THE TIMES | Saturday May 11 2013 FGM

# Happy and healthy, the child saved by surgery that stopped him dying in womb at 21 weeks

Spain

#### Graham Keeley Madrid

When Gonzalo Pardo Sánchez's parents discovered that their unborn baby had a life-threatening condition in the womb, they were at first advised to have an abortion.

Gonzalo was suffering from congenital high airway obstruction syndrome (Chaos), which stopped his lungs from expelling fluid through the trachea.

Purely by chance, their doctor in Almería heard that a team from two research hospitals in Barcelona had performed three operations to try to save foetuses with this unusual condition. Those operations had proved unsuccessful but, after having the same procedure, Gonzalo survived.

Yesterday, doctors confirmed that the baby, now ten months old.



Gonzalo Pardo Sánchez, with his mother María, is now ten months old and in good health after the ground-breaking surgery in Barcelona heart. Weeks after the operation, he was born healthy without any respiratory problems.

Today Gorzalo sounds like any normal ten-month-old and has come through two health checks. The operation has been performed on four other occasions around the world but the children have either died or suffered brain damage or serious respiratory problems.

Surgery on unborn babies is extremely rare but has become established as an option for life-threatening problems that cannot wait until a baby is born. It was first successfully attempted in San Francisco in 1981 when a baby named Michael Skinner had a blocked urinary tract repaired. He is now a healthy adult. Since then it has been used regularly for conditions such as tumours and spina bifida. Kino's College Hospital in

First saved foetus in the world with congenital high airway obstruction syndrome by foetal surgery at 21 weeks of pregnancy















# First time in Europe of the Argus II artificial sight chip 2015











# TaTME technique for the treatment of colon and rectal cancer. Worldwide pioneers










## **3D surgical navigation for Foetal Surgery**









### **PERORAL ENDOSCOPIC MYOTOMY - POEM**









# First centre in Spain to have the new guided robot for spinal pathology. Mazor XTM robotic platform










# First hospital Spain Transorbital Skull Base Surgery










# **International Expansion**









# **THANK YOU!**

### www.barcelonamedicaldestination.com

barcelonamedicaldestination@gencat.cat